Pancreatic endocrine tumors constitute a wide variety of rare lesions that are named according to the hormones that they produce. The most common pancreatic islet cell tumors are insulinoma and gastrinoma, followed in frequency of diagnosis by glucagonomas and vasoactive intestinal peptide (VIP)omas. Somatostatinomas are even more unusual. Nonfunctioning neoplasms with morphological features of islet cell tumors constitute 30% of pancreatic islet cell tumors . According to a report from Japan Pancreas Society (JPS) , of 11,819 epithelial tumors, 307 cases were with endocrine tumors and the cumulative 5-year survival of the patients after pancreatectomy for islet cell tumor in Japan is 74.3%, while that of the patients with nonfunctioning islet cell tumor is 50%. The 5-year survival of the patients of stage IVa and IVb (of JPS) were 62.1% and 39.4% and was significantly lower than that of patients disease of other stages (Fig. 66.1). We describe herein details of the surgical outcome of endocrine tumors of pancreas.
ASJC Scopus subject areas